332 related articles for article (PubMed ID: 20074687)
21. A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.
Schmeisser F; Vasudevan A; Soto J; Kumar A; Williams O; Weir JP
Influenza Other Respir Viruses; 2014 Sep; 8(5):587-95. PubMed ID: 25087462
[TBL] [Abstract][Full Text] [Related]
22. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.
Khurana S; King LR; Manischewitz J; Coyle EM; Golding H
Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520
[TBL] [Abstract][Full Text] [Related]
23. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
[TBL] [Abstract][Full Text] [Related]
24. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
25. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
26. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
[TBL] [Abstract][Full Text] [Related]
27. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
28. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.
Khurana S; Larkin C; Verma S; Joshi MB; Fontana J; Steven AC; King LR; Manischewitz J; McCormick W; Gupta RK; Golding H
Vaccine; 2011 Aug; 29(34):5657-65. PubMed ID: 21704111
[TBL] [Abstract][Full Text] [Related]
29. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
[TBL] [Abstract][Full Text] [Related]
30. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
[TBL] [Abstract][Full Text] [Related]
31. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL
Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022
[TBL] [Abstract][Full Text] [Related]
32. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
33. A hemagglutinin quantification method for development of an influenza pandemic vaccine using size exclusion high performance liquid chromatography.
Roh HS; Song HM; Yun BR; Kang HK; Choi KS; Park YJ; Kim DS; Kim SH; Mo IP; An BS; Ahn CY
Mol Med Rep; 2015 Apr; 11(4):2819-24. PubMed ID: 25482872
[TBL] [Abstract][Full Text] [Related]
34. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.
Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC
Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201
[TBL] [Abstract][Full Text] [Related]
35. Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays.
Vasudevan A; Woerner A; Schmeisser F; Verma S; Williams O; Weir JP
Influenza Other Respir Viruses; 2018 Mar; 12(2):250-258. PubMed ID: 29152878
[TBL] [Abstract][Full Text] [Related]
36. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
[TBL] [Abstract][Full Text] [Related]
37. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
38. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
39. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.
Veits J; Römer-Oberdörfer A; Helferich D; Durban M; Suezer Y; Sutter G; Mettenleiter TC
Vaccine; 2008 Mar; 26(13):1688-96. PubMed ID: 18291561
[TBL] [Abstract][Full Text] [Related]
40. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
